A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4156 participants.

Also called NCT01455896

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 4,156 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01455896
Other papers using this trial's data
  • Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial Nature medicine, 2022-01 DOI, PubMed 34873344

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Bulgaria, Denmark, Finland, Germany, Poland, Slovakia, South Africa, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01455896. Randomized; quadruple masking; primary purpose treatment. Start 2013-03 (actual); primary completion 2016-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
Intervention (Drug)
ITCA 650
Intervention (Other)
ITCA placebo
Lead sponsor
Intarcia Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct01455896
Content hash
afb37c498478549f39dc95c90a4767fff818464ad967d4b84348c99b0e1140d4